TIDMOPTI
RNS Number : 8781L
OptiBiotix Health PLC
05 May 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Distribution of products in China and Hong Kong
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces it has entered into a three-year distribution
agreement with Pierce Group Asia subsidiary, Pierce ESIM Pte
Limited ("Pierce").
Founded in 2002 and headquartered in Singapore, Pierce
specialises in cross border corporate development and investments
with a focus on high growth partnerships. Pierce is an Asian
focused B2B product developer and distributor with an experienced
leadership team and extensive corporate network.
The agreement grants Pierce exclusive rights to import and
commercialise OptiBiotix's SlimBiome(R) and LPLDL(R) to
manufacture, develop, and sell a wide range of finished products to
China and Hong Kong, with the aim of maximising the financial
return for both parties. Under the agreement, Pierce will also
conduct business development activities in other Asia-Pacific
geographies to advance OptiBiotix's commercial interests. Market
exclusivity is linked to minimum yearly order quantities.
This agreement is an important step in meeting the growing need
for weight management and cardiovascular products in the large
consumer markets of China and the Asia Pacific.
-- China has the largest number of overweight or obese people
worldwide with about 46% of adults and 15% of children being obese
or overweight (Wang, Y. Lancet 2019)
-- Non-communicable diseases account for 87% of total adult
deaths in China of which cardiovascular diseases ("CVD") account
for almost half (45%)*
-- China has one of the highest CVD death rates in the world
with one in five adults in China estimated to have cardiovascular
disease*
-- The Chinese Vitamins, Minerals & Supplements industry
increased 9.2% between 2017 and 2018 to reach a total market size
of US$21 billion**
* World Heart Federation factsheet 2017
**TMO Group 2019
This agreement represents another strategic step to take
OptiBiotix's SlimBiome(R) and LPLDL(R) to international markets and
follows on from the announcement of over 60 commercial agreements
in the last three years. These include deals for Gulf Cooperation
Countries (RNS: 17 March 2020); Australasia (RNS: 31 March 2020);
Europe including Italy (RNS 21 June 2018) , Germany (RNS 15 March
2019), Russia (RNS: 9 January 2019); India (RNS: 16 May 2018 and 7
January 2019); South America (RNS: 12 February 2020) and the USA
(RNS: 22 May 2018 and 31 January 2020).
Mike McGeever, Chairman of Pierce said : "We are pleased to be
working with OptiBiotix in marketing and distributing their
products to the large and growing Chinese and Hong Kong markets. We
believe in the benefits that OptiBiotix product portfolio will
bring to the people of China and Hong Kong to address growing rates
in obesity and other chronic diseases. We will leverage our team's
experience in Asia and within the health sector to deliver a
partnership of value for both parties."
Stephen O'Hara, CEO of OptiBiotix, said: We are pleased to
announce this agreement with Pierce. We chose Pierce due to their
team's experience in working with large corporates and major
retailers across Asia. Their leadership team have a track record of
corporate deal making in the complex Asian market and an extensive
regional network. We believe partnering with Pierce is an important
step in accessing the large and growing Chinese and Hong Kong
health market. We hope the combination of our strong science,
growing global brands, and Pierce's local knowledge and expertise
will help bring the benefits of SlimBiome(R) and LPLDL(R) to
China's 350m obese and 290m patients with cardiovascular disease .
We believe working with Pierce, and similar partners around the
world, provides the best opportunity of increasing our global
commercial reach and catering for the growing interest we are
seeing in our products from partners worldwide."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
About Pierce - www.pierceesim.com
Founded in 2002, Pierce ESIM Pte Limited is an operating
subsidiary of Pierce Group Asia Pte Limited and is headquartered in
Singapore. Pierce ESIM is at the forefront of delivering to its
partners and customers leading intellectual property solutions.
With an Asia-Pacific focus, we bring innovative solutions to our
customers and offer our own range of customisable white label
products ready for distribution to wholesale customers and retail
consumers.
Pierce's leadership team includes Mike McGeever, an experienced
global business executive , growth specialist David Cronin, with 18
years' experience of Asia, Dave Battiston, a cross border
partnership specialistwith significant relationships with large
corporates, and Angela Low who has a deep understanding of local
markets, being born and raised in South East Asia.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRFLFFREFISIII
(END) Dow Jones Newswires
May 05, 2020 05:21 ET (09:21 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024